Clinical Pharmacokinetics

, Volume 57, Issue 5, pp 613–623 | Cite as

Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials

  • Amit Khatri
  • Sandra Goss
  • Ping Jiang
  • Heikki Mansikka
  • Ahmed A. Othman
Original Research Article


Background and Objective

ABT-122 is a dual-variable domain immunoglobulin that neutralizes both tumor necrosis factor-α and interleukin-17A, with the goal of achieving greater clinical efficacy than can be achieved by blocking either cytokine alone. This work characterized the pharmacokinetics of ABT-122 in healthy subjects and in patients with rheumatoid arthritis.


ABT-122 pharmacokinetics was evaluated in three phase I studies. In Study 1, single intravenous (0.1, 0.3, 1, 3, and 10 mg/kg) and subcutaneous (0.3, 1, and 3 mg/kg) doses were evaluated in healthy subjects. In Studies 2 and 3, multiple subcutaneous doses (1 mg/kg every other week or 0.5–3 mg/kg every week) were evaluated for 8 weeks in patients with rheumatoid arthritis on stable methotrexate therapy. Pharmacokinetic data were available from 48 healthy subjects and 31 patients with rheumatoid arthritis.


ABT-122 showed multi-exponential disposition with more than dose-proportional exposures at the 0.1–1 mg/kg doses and approximately dose-proportional exposures at doses ≥1 mg/kg. ABT-122 absolute subcutaneous bioavailability was approximately 50% with maximum serum concentrations observed 3–4 days after dosing. Steady state was achieved by week 6 of subcutaneous dosing. ABT-122 maximum serum concentration-to-trough concentration ratio was 2.6 for every other week dosing and 1.3 for every week dosing, corresponding to an effective half-life of 10–18 days. ABT-122 median area under the serum concentration–time curve accumulation ratio was 3.8–4.8 with every week dosing. Measureable antidrug antibodies were observed in all 48 subjects in Study 1 by day 15 post-dose and 19 of 31 ABT-122-treated patients in Studies 2 and 3 [median time to appearance of antidrug antibodies of 64 days (range 15–92 days)]. No dose-limiting toxicities were observed in these studies and the maximum tolerated dose was not identified.


Results from these three phase I studies supported testing ABT-122 every week and every other week regimens in phase II trials in subjects with rheumatoid and psoriatic arthritis. Study 2 (EudraCT: 2012-003448-54); Study 3 (NCT01853033)



The authors thank Allison Kitten, PhD, an employee of AbbVie, for medical writing support.

Compliance with Ethical Standards


The studies were sponsored by AbbVie. AbbVie contributed to the study designs, research, and interpretation of data, and the writing, review, and approval of the publication.

Conflict of interest

Amit Khatri, Sandra Goss, Ping Jiang, Heikki Mansikka, and Ahmed A. Othman are employees of AbbVie and may hold AbbVie stock or stock options.

Ethics approval

The studies were conducted in accordance with Good Clinical Practice guidelines and the ethical principles that have their origin in the Declaration of Helsinki. The protocols and informed consent forms were approved by the institutional review boards at each site.

Consent to participate

All participants provided written informed consent before any study-related procedures were performed.


  1. 1.
  2. 2.
    Centers for Disease Control and Prevention. Rheumatoid arthritis (RA). Accessed 11 July 2017.
  3. 3.
    European Federation of Pharmaceutical Industries and Associations. Rheumatoid arthritis. Accessed 11 July 2017.
  4. 4.
    Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi: 10.1136/annrheumdis-2013-204573.CrossRefPubMedGoogle Scholar
  5. 5.
    Nirula A, Nilsen J, Klekotka P, Kricorian G, Erondu N, Towne JE, et al. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases. Rheumatology (Oxford). 2016;55(Suppl. 2):ii43–55. doi: 10.1093/rheumatology/kew346.CrossRefGoogle Scholar
  6. 6.
    Kunwar S, Dahal K, Sharma S. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol Int. 2016;36(8):1065–75. doi: 10.1007/s00296-016-3480-9.CrossRefPubMedGoogle Scholar
  7. 7.
    Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516–28. doi: 10.1136/annrheumdis-2013-204577.CrossRefPubMedGoogle Scholar
  8. 8.
    Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–76. doi: 10.1038/nrd3794.CrossRefPubMedGoogle Scholar
  9. 9.
    Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J, et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum. 2011;63(8):2329–39. doi: 10.1002/art.30418.CrossRefPubMedGoogle Scholar
  10. 10.
    van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum. 2011;63(1):73–83. doi: 10.1002/art.30093.CrossRefPubMedGoogle Scholar
  11. 11.
    Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006;54(4):1122–31. doi: 10.1002/art.21749.CrossRefPubMedGoogle Scholar
  12. 12.
    Hsieh C-M, Cuff C, Tarcsa E, Hugunin M. FRI0303 Discovery and characterization of ABT-122, an anti-TNF/IL-17 DVD-Ig™ molecule as a potential therapeutic candidate for rheumatoid arthritis. Ann Rheum Dis. 2014;73(Suppl. 2):495. doi: 10.1136/annrheumdis-2014-eular.4676.Google Scholar
  13. 13.
    Fleischmann R, Wagner F, Kivitz AJ, Mansikka H, Khan N, Othman AA, et al. Safety, tolerability, and pharmacodynamics of ABT-122, a TNF- and IL-17-targeted dual variable domain immunoglobulin, in patients with RA. Arthritis Rheum. 2017 (submitted).Google Scholar
  14. 14.
    Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79. doi: 10.1016/j.pharmthera.2007.10.001.CrossRefPubMedGoogle Scholar
  15. 15.
    Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016;22(3):230–41. doi: 10.1016/j.molmed.2016.01.001.CrossRefPubMedGoogle Scholar
  16. 16.
    Mansikka H, Ruzek M, Hugunin M, Ivanov A, Brito A, Clabbers A, et al. Safety, tolerability, and functional activity of ABT-122, a dual TNF- and IL-17A–targeted DVD-Ig™, following single-dose administration in healthy subjects. Ann Rheum Dis. 2015;74(Suppl. 2):482–3.Google Scholar
  17. 17.
    Cuff C, Ruzek M, Padley R, Mansikka H, Voss J, Hugunin M, et al. Mechanisms of dual inhibition of TNF and IL-17: translation to clinical studies with ABT-122. Inflamm Res. 2015;64(2):S98–9. doi: 10.1007/s00787-015-0714-4.Google Scholar
  18. 18.
    Cuff C, Bryant S, Hugunin M, Kamath R, Voss J, Olson L, et al. Dual neutralization of TNF and IL-17 with a DVD-Ig protein is efficacious in collagen induced arthritis. Ann Rheum Dis. 2014;73:363. doi: 10.1136/annrheumdis-2014-eular.5383.CrossRefGoogle Scholar
  19. 19.
    van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–16. doi: 10.1136/ard.2003.013052.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    AbbVie. Adalimumab (US prescribing information). North Chicago: AbbVie; 2017.Google Scholar
  21. 21.
    Janssen Biotech, Inc. Infliximab (US prescribing information). Horsham: Janssen Biotech, Inc.; 2015.Google Scholar
  22. 22.
    Novartis. Secukinumab (US prescribing information). East Hanover: Novartis; 2016.Google Scholar
  23. 23.
    Eli Lilly and Company. Ixekizumab (US prescribing information). Indianapolis: Eli Lilly and Company; 2016.Google Scholar
  24. 24.
    Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016;21–22:75–83. doi: 10.1016/j.ddtec.2016.09.004.CrossRefPubMedGoogle Scholar
  25. 25.
    Janssen Biotech, Inc. Golimumab (US prescribing information). Horsham: Janssen Biotech, Inc.; 2017.Google Scholar
  26. 26.
    Immunex Corporation. Etanercept (US prescribing information). Thousand Oaks: Immunex Corporation; 2009.Google Scholar
  27. 27.
    Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–67. doi: 10.1016/j.immuni.2008.03.004.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. Virulence. 2010;1(5):423–7. doi: 10.4161/viru.1.5.12862.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Amit Khatri
    • 1
  • Sandra Goss
    • 1
  • Ping Jiang
    • 1
  • Heikki Mansikka
    • 1
  • Ahmed A. Othman
    • 1
  1. 1.AbbVie IncNorth ChicagoUSA

Personalised recommendations